Key insights
- Intuitive Surgical's EVP Gary Loeb sold 400 shares. ISRG is down 26% in six months and trading near its 52-week low. ServiceNow cited the U.S.-Iran war impacting subscription revenue. IBM surpassed forecasts but maintained guidance. ISRG's Q1 results beat expectations, with sales up 23% and EPS up 38%. Some analysts lowered price targets despite strong growth, while others maintained positive ratings due to raised guidance and margins. Overall, the news is slightly negative due to the executive stock sale and price target reductions.
Gary Loeb, Executive Vice President and Chief Legal and Compliance Officer at Intuitive Surgical Inc (NASDAQ:ISRG), sold 400 shares of the company’s common stock on May 11, 2026. The transaction totaled $178,780.
The shares were sold at a price of $446.95 per share. Following this transaction, Mr. Loeb directly owns 6,120 shares of Intuitive Surgical common stock. The sale was conducted in accordance with a Rule 10b5-1 trading plan, which is set to expire on January 29, 2027.The stock has declined since the transaction, currently trading at $420.06, near its 52-week low of $417.74. The shares are down 26% over the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels. For deeper insights, investors can access the comprehensive Pro Research Report, available for ISRG and 1,400+ other US equities.
In other recent news, ServiceNow and IBM have reported their latest earnings, which have sparked significant reactions in the software sector. ServiceNow slightly exceeded Wall Street expectations but mentioned that the U.S.-Iran war is impacting its subscription revenue. Meanwhile, IBM surpassed earnings and revenue forecasts but opted to maintain its current guidance. Intuitive Surgical has also been in the spotlight after delivering first-quarter results that surpassed consensus estimates for both revenue and earnings. RBC Capital noted that Intuitive Surgical’s sales increased by 23% year-over-year, with earnings per share growing by 38%, beating expectations by 18%. Piper Sandler and Barclays have both lowered their price targets for Intuitive Surgical, despite strong volume growth and system sales. RBC Capital and Bernstein have maintained their positive ratings on Intuitive Surgical, with Bernstein highlighting the company’s raised guidance and robust margins. These developments reflect the dynamic landscape in the tech and medical device sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.